by Lacour et al [1] give cause for concern. Concentrations of lanthanum in plasma for control samples were of the order of 400 ng/mL, and values were not significantly elevated in rats given lanthanum carbonate. In independent studies we, and others, have obtained background levels 1000 to 10,000 times lower and routinely differentiate plasma from control and lanthanum-treated groups (see Fig. 1 ) [2]. In dialysis patients treated with recommended doses of Fosrenol , steady state plasma concentrations are <1 ng/mL [3] (see also Prescribing Information), 400 times lower than in the placebo samples in the Lacour et al [1] rat study. These results strongly suggest contamination of analytical samples with lanthanum from the animals' environment.
Values are mean ± SD; N = 6; LLoQ (lower limit of quantification) = 0.05 ng/mL; values <LLoQ reported as 0.05 ng/mL. Manuscript in preparation.
Reply from the Author
We thank McLeod et al for having drawn attention to an error in Figure 3A of our article published in a recent issue of Kidney International [1] . The unit of plasma lanthanum has been erroneously indicated as 'lg/mL' when in fact it should read 'lg/L,' as shown by the scan of a randomly selected original laboratory sheet of the lanthanum determinations done in our study (Fig. 1) . We sent an erratum to the Editors earlier this month when we became aware of this regrettable typographic error. The erratum was published in the July 2005 issue.
We agree that every possible precaution should be taken to avoid contamination of plasma and tissue samples by trace elements when given in large amounts to experimental animals or man. It is true that in our study, rats received lanthanum carbonate in their food, not by gavage like in the study by Behets et al [2] . Nevertheless, lanthanum tissue concentrations found in our study were of same order of magnitude as those of the latter study. Thus, the mean bone lanthanum content was near 300 ng/g (lg/kg) wet weight in the lanthanum carbonateoverloaded uremic rats of our study and near 1500 lg/kg wet weight in their lanthanum carbonate-overloaded uremic rats. One has to consider that the animals of our study ingested approximately 1800 mg/kg lanthanum carbonate per day for a time period of only 4 weeks, whereas the rats of their study were gavaged with a maximal daily dose of 1000 mg/kg lanthanum carbonate for a time period of 3 months. When correcting for this time factor, it is fair to conclude that the measurements in the two studies yielded comparable results. The lanthanum measurement techniques were the same, namely, inductively coupled plasma emission spectrometry.
McLeod et al point out that they and others routinely differentiate plasma lanthanum concentrations measured in lanthanum-treated groups from those determined in control samples. They show Figure 1 demonstrating plasma lanthanum concentrations before and after an acute dose of lanthanum carbonate given to rats. However, when analyzing Figure 1 closely, it becomes apparent that the plasma lanthanum concentration (near 350 lg/L) found 24 hours after the acute dose was probably not different from the lanthanum concentration in control plasma samples. Note that the latter was below the lower limit of quantification. In the rats of our study, lanthanum carbonate was not given as an acute load, but was ingested progressively during 24 hours. Therefore, one would not expect a peak plasma concentration such as the one shown in McLeod et al's figure, but rather a concentration near to the bottom line. This is exactly what we found (200-500 lg/L).
In our opinion, the suspicion of sample contamination that has been formulated based on a typographic error in one of the figures of our article can be ruled out with a reasonable degree of confidence. BERNARD To the Editor: On the basis of higher urine lanthanum recoveries in uremic rats, Lacour et al [1] conclude there are "important differences in the pharmacokinetics of lanthanum in chronic renal failure." This seems not to be the case in man. Indeed, in a series of Phase I studies carried out to support the development of Fosrenol , plasma concentration versus time profiles, and pharmacokinetic parameters (C max , AUC 0−t, t1 / 2 abs , and t1 / 2 elim ) were similar in healthy subjects and dialysis patients (see Fig. 1 , p. 2908) [2] , excluding a significant role of the kidney in the elimination of lanthanum and suggesting little influence of end-stage renal disease (ESRD) on systemic bioavailability. It is possible that higher absorption and, hence, higher portal plasma and liver lanthanum concentrations may occur in renal failure without affecting systemic plasma profiles, but no data are available on this at the present time.
Sample contamination may have influenced the Lacour et al [1] rat data, as plasma lanthanum concentrations in the controls in this study were extremely high compared to other studies [3] . Inevitably, there is contact between urine, feces, and spilled diet in standard rodent metabolism cages and, hence, an opportunity exists for the high concentrations of lanthanum present in diet and feces to transfer to urine. The extent of contamination will be proportional to the volume of urine washing over cage surfaces and, as Lacour et al [1] highlight, urine volume was markedly elevated in the uremic groups. Such contamination is a common source of error in rat excretion studies, particularly when poorly absorbed drugs, present at very low concentrations (nmol/L) in body tissues and fluids, are administered via the diet [4] . The potential for contamination can be reduced by controlled gavage of the drug directly into the stomach of the rats.
